Reduced bioavailability of oral amoxicillin tablets compared to suspensions in Roux‐en‐Y gastric bypass bariatric subjects

Reduced bioavailability of oral amoxicillin tablets compared to suspensions in Roux‐en‐Y gastric bypass bariatric subjects

Aims To evaluate the relative bioavailability of oral amoxicillin (AMX) tablets in comparison to AMX suspension in Roux‐en‐Y gastric bypass bariatric subjects. Methods A randomized, double‐blind, cross‐over study was performed on the bioavailability of oral AMX tablets and suspension in Roux‐en‐Y ga...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology Vol. 85; no. 9; pp. 2118 - 2125
Main Authors: Montanha, Maiara Camotti, Santos Magon, Thiago Ferreira, Souza Alcantara, Conrado, Simões, Caroline Ferraz, Silva, Sandra Regina Bin, Kuroda, Cristina Megumi, Yamada, Sérgio Seiji, Oliveira, Lucas Eduardo Savóia, Nasser, Daoud, Junior, Nelson Nardo, Mazucheli, Josmar, Diniz, Andrea, Paixão, Paulo Jorge Pereira Alves, Kimura, Elza
Format: Journal Article
Language:English
Published: England John Wiley and Sons Inc 01-09-2019
Subjects:
Administration, Oral
Adult
amoxicillin
Amoxicillin - administration & dosage
Amoxicillin - blood
Amoxicillin - pharmacokinetics
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - blood
Anti-Bacterial Agents - pharmacokinetics
Area Under Curve
Biological Availability
Cross-Over Studies
Double-Blind Method
Female
gastric bypass
Gastric Bypass - adverse effects
Humans
Male
Middle Aged
Original
pharmacokinetic
relative bioavailability
Suspensions
Tablets
amoxicillin
relative bioavailability
pharmacokinetic
gastric bypass
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims To evaluate the relative bioavailability of oral amoxicillin (AMX) tablets in comparison to AMX suspension in Roux‐en‐Y gastric bypass bariatric subjects. Methods A randomized, double‐blind, cross‐over study was performed on the bioavailability of oral AMX tablets and suspension in Roux‐en‐Y gastric bypass subjects operated at least 3 months previously . Doses of 875 mg of the AMX tablet or 800 mg of the AMX suspension were given to all the subjects, allowing a washout of 7 days between the periods. Blood samples were collected at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6 and 8 hours after drug administration and the AMX levels were quantified by liquid chromatography coupled with triple quadrupole tandem mass spectrometry. The pharmacokinetic parameters were calculated by noncompartmental analysis, normalized to an 875 mg dose and the bioavailability of the AMX from the tablets was compared to that from the suspension formulation. Results Twenty subjects aged 42.65 ± 7.21 years and with a body mass index of 29.88 ± 4.36 kg/m2 were enrolled in the study. The maximum AMX plasma concentration of the tablets and the suspension (normalized to 875 mg) were 7.42 ± 2.99 mg/L and 8.73 ± 3.26 mg/L (90% confidence interval of 70.71–99.11), and the total area under the curve from time zero to infinity were 23.10 ± 7.41 mg.h/L and 27.59 ± 8.32 mg.h/L (90% confidence interval of 71.25–97.32), respectively. Conclusion The tablets presented a lower bioavailability than the suspension formulation and the total absorbed amount of AMX in these subjects was lower in comparison to the standard AMX absorption rates in nonbariatric subjects, regardless of the formulation.
Bibliography:The authors confirm that the PI for this paper is Sérgio Seiji Yamada and that he had direct clinical responsibility for the patients.
ISSN:0306-5251
1365-2125
DOI:10.1111/bcp.14023